KR20050084424A - 케모킨 수용체 ｃｃｒ5의 조절제로서 신규한 피페리딘유도체 - Google Patents
케모킨 수용체 ｃｃｒ5의 조절제로서 신규한 피페리딘유도체 Download PDFInfo
- Publication number
- KR20050084424A KR20050084424A KR1020057011450A KR20057011450A KR20050084424A KR 20050084424 A KR20050084424 A KR 20050084424A KR 1020057011450 A KR1020057011450 A KR 1020057011450A KR 20057011450 A KR20057011450 A KR 20057011450A KR 20050084424 A KR20050084424 A KR 20050084424A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- phenyl
- heteroaryl
- compound
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0203821A SE0203821D0 (sv) | 2002-12-20 | 2002-12-20 | Chemical Compounds |
| SE0203821-4 | 2002-12-20 | ||
| SE0300499A SE0300499D0 (sv) | 2003-02-24 | 2003-02-24 | Chemical compounds |
| SE0300499-1 | 2003-02-24 | ||
| SE0301425-5 | 2003-05-15 | ||
| SE0301425A SE0301425D0 (sv) | 2003-05-15 | 2003-05-15 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20050084424A true KR20050084424A (ko) | 2005-08-26 |
Family
ID=32685861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020057011450A Withdrawn KR20050084424A (ko) | 2002-12-20 | 2003-12-18 | 케모킨 수용체 ｃｃｒ5의 조절제로서 신규한 피페리딘유도체 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20060189650A1 (https=) |
| EP (1) | EP1572650A1 (https=) |
| JP (1) | JP2006514107A (https=) |
| KR (1) | KR20050084424A (https=) |
| AR (1) | AR042628A1 (https=) |
| AU (1) | AU2003288856B2 (https=) |
| BR (1) | BR0317459A (https=) |
| CA (1) | CA2508624A1 (https=) |
| CL (1) | CL2003002678A1 (https=) |
| CO (1) | CO5570665A2 (https=) |
| IS (1) | IS7942A (https=) |
| MX (1) | MXPA05006381A (https=) |
| NZ (1) | NZ540780A (https=) |
| PL (1) | PL377768A1 (https=) |
| TW (1) | TW200505856A (https=) |
| UY (1) | UY28139A1 (https=) |
| WO (1) | WO2004056773A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0103818D0 (sv) | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
| SE0301369D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Chemical compounds |
| SE0302090D0 (sv) * | 2003-07-16 | 2003-07-16 | Astrazeneca Ab | Chemical compounds |
| ATE361911T1 (de) * | 2003-07-31 | 2007-06-15 | Astrazeneca Ab | Piperidinderivate als ccr5-rezeptormodulatoren |
| TW200610761A (en) * | 2004-04-23 | 2006-04-01 | Astrazeneca Ab | Chemical compounds |
| RU2006146608A (ru) | 2004-06-09 | 2008-07-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | ОКТАГИДРОПИРРОЛО[3,4-с]-ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ АГЕНТОВ |
| SE0401656D0 (sv) * | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | Chemical compounds |
| SE0401657D0 (sv) * | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | Chemical compounds |
| US7665658B2 (en) | 2005-06-07 | 2010-02-23 | First Data Corporation | Dynamic aggregation of payment transactions |
| WO2007045573A1 (en) | 2005-10-19 | 2007-04-26 | F. Hoffmann-La Roche Ag | Phenyl-acetamide nnrt inhibitors |
| CA2658984C (en) | 2006-08-16 | 2014-12-02 | Joshua Kennedy-Smith | Non-nucleoside reverse transcriptase inhibitors |
| CA2664364A1 (en) * | 2006-09-28 | 2008-04-03 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
| CN101553483B (zh) | 2006-12-13 | 2013-04-17 | 弗·哈夫曼-拉罗切有限公司 | 作为非核苷逆转录酶抑制剂的2-(哌啶-4-基)-4-苯氧基-或苯基氨基-嘧啶衍生物 |
| SG181900A1 (en) | 2009-12-23 | 2012-08-30 | Ironwood Pharmaceuticals Inc | Crth2 modulators |
| US20130216552A1 (en) | 2010-07-12 | 2013-08-22 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| WO2012009134A1 (en) | 2010-07-12 | 2012-01-19 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| WO2018068296A1 (en) | 2016-10-14 | 2018-04-19 | Merck Sharp & Dohme Corp. | PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
| CN113444065A (zh) * | 2021-06-29 | 2021-09-28 | 浙江得乐康食品股份有限公司 | 一种莽草酸磺化物及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9100513A (es) * | 1990-08-06 | 1992-04-01 | Smith Kline French Lab | Compuestos |
| IL125658A0 (en) * | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| EP1013276A1 (en) * | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
| AU5600100A (en) * | 1999-06-11 | 2001-01-02 | Merck & Co., Inc. | Cyclopentyl modulators of chemokine receptor activity |
| GB0011838D0 (en) * | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
| GB0013060D0 (en) * | 2000-05-31 | 2000-07-19 | Astrazeneca Ab | Chemical compounds |
| GB0108046D0 (en) * | 2001-03-30 | 2001-05-23 | Astrazeneca Ab | Chemical compounds |
| WO2003062224A1 (en) * | 2002-01-17 | 2003-07-31 | Eli Lilly And Company | Aza-cyclic compounds as modulators of acetylcholine receptors |
-
2003
- 2003-12-17 AR ARP030104682A patent/AR042628A1/es not_active Application Discontinuation
- 2003-12-18 KR KR1020057011450A patent/KR20050084424A/ko not_active Withdrawn
- 2003-12-18 EP EP03781235A patent/EP1572650A1/en not_active Withdrawn
- 2003-12-18 CL CL200302678A patent/CL2003002678A1/es unknown
- 2003-12-18 US US10/539,859 patent/US20060189650A1/en not_active Abandoned
- 2003-12-18 WO PCT/SE2003/002008 patent/WO2004056773A1/en not_active Ceased
- 2003-12-18 MX MXPA05006381A patent/MXPA05006381A/es active IP Right Grant
- 2003-12-18 PL PL377768A patent/PL377768A1/pl not_active Application Discontinuation
- 2003-12-18 JP JP2005502630A patent/JP2006514107A/ja active Pending
- 2003-12-18 CA CA002508624A patent/CA2508624A1/en not_active Abandoned
- 2003-12-18 NZ NZ540780A patent/NZ540780A/en unknown
- 2003-12-18 AU AU2003288856A patent/AU2003288856B2/en not_active Ceased
- 2003-12-18 BR BR0317459-0A patent/BR0317459A/pt not_active IP Right Cessation
- 2003-12-19 TW TW092136170A patent/TW200505856A/zh unknown
- 2003-12-19 UY UY28139A patent/UY28139A1/es unknown
-
2005
- 2005-06-13 CO CO05057099A patent/CO5570665A2/es not_active Application Discontinuation
- 2005-07-18 IS IS7942A patent/IS7942A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2508624A1 (en) | 2004-07-08 |
| PL377768A1 (pl) | 2006-02-20 |
| AU2003288856A1 (en) | 2004-07-14 |
| MXPA05006381A (es) | 2005-08-29 |
| IS7942A (is) | 2005-07-18 |
| US20060189650A1 (en) | 2006-08-24 |
| CO5570665A2 (es) | 2005-10-31 |
| JP2006514107A (ja) | 2006-04-27 |
| TW200505856A (en) | 2005-02-16 |
| NZ540780A (en) | 2008-04-30 |
| EP1572650A1 (en) | 2005-09-14 |
| BR0317459A (pt) | 2005-11-16 |
| AR042628A1 (es) | 2005-06-29 |
| WO2004056773A1 (en) | 2004-07-08 |
| CL2003002678A1 (es) | 2005-04-22 |
| AU2003288856B2 (en) | 2006-11-16 |
| UY28139A1 (es) | 2004-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20060167048A1 (en) | N-4-piperidinyl compounds as ccr5 modulators | |
| KR20050084424A (ko) | 케모킨 수용체 ｃｃｒ5의 조절제로서 신규한 피페리딘유도체 | |
| CN1938274A (zh) | 用作趋化因子调节剂(ccr)的新哌啶化合物 | |
| US20060069120A1 (en) | Novel piperidine derivaties as modulators of chemokine receptor ccr5 | |
| US7294636B2 (en) | Chemical compounds | |
| US20060052413A1 (en) | Novel piperidine derivatives as modulators of chemokine receptor ccr5 | |
| EP1648871B1 (en) | Piperidine or 8-aza-bicyclo 3.2.1 oct-3-yl derivatives useful as modulators of chemokine receptor activity | |
| EP1654229B1 (en) | Piperidine derivatives as ccr5 receptor modulators | |
| US20080200460A1 (en) | Chemical Compounds | |
| WO2005058881A1 (en) | Chemical compounds | |
| US20080139612A1 (en) | Chemical Compound | |
| ZA200504616B (en) | Novel piperidine derivatives as modulators of chemokine receptor CCR5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20050617 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |